EIKNEikon Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Eikon Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EIKN본 종목 | $513M#7 | — | 1.1x#2 | — | — | — | — | 0.0%#1 | — | — | — | — |
| CADL | $852M#1 | — | 6.8x#12 | 6813.2x#6 | 0.0%#6 | 30.8%#3 | -38612.8%#7 | -30.3%#5 | — | — | 129.7%#3 | — |
| FDMT | — | — | — | — | 230194.6%#1 | 12.9%#6 | -187.2%#3 | -34.4%#7 | -44.7%#2 | — | 100.4%#4 | — |
| AURA | $721M#2 | — | 2.3x#7 | — | — | -22.2%#9 | — | -33.7%#6 | — | — | 16.0%#8 | — |
| ALLO | $596M#3 | — | 1.4x#4 | — | -100.0%#8 | 25.9%#4 | — | -43.8%#9 | — | — | 50.0%#6 | — |
| PRME | $571M#4 | — | 14.4x#15 | 123.3x#5 | 55.3%#3 | -2.7%#8 | -4498.1%#6 | -505.3%#15 | — | — | -21.4%#11 | — |
| TECX | $556M#5 | — | 2.5x#8 | — | — | -27.9%#11 | — | -33125.9%#16 | -713.5%#4 | — | 71.1%#5 | — |
| RGNX | $524M#6 | — | 7.3x#13 | 3.1x#2 | 104.5%#2 | 14.6%#5 | -94.6%#1 | -270.2%#14 | — | — | -12.7%#10 | — |
| ZURA | $471M#9 | — | 4.6x#11 | — | — | -31.0%#13 | — | -67.6%#10 | — | — | 156.3%#2 | — |
| DNA | $447M#10 | — | 1.1x#1 | 2.6x#1 | -25.1%#7 | 42.8%#1 | -185.3%#2 | -0.1%#2 | — | — | -31.7%#12 | — |
| CABA | $439M#11 | — | 2.1x#6 | — | — | -44.9%#14 | — | -79.7%#11 | — | — | 35.2%#7 | — |
| ARTV | $435M#12 | — | 1.3x#3 | — | -100.0%#8 | -28.3%#12 | — | -24.1%#4 | — | — | 281.8%#1 | — |
| KYTX | $432M#13 | — | 2.6x#9 | — | — | -26.5%#10 | — | -97.4%#12 | -107.1%#3 | — | — | — |
| CCCC | $423M#14 | — | 1.7x#5 | 11.8x#4 | 1.0%#5 | 0.3%#7 | -320.5%#4 | -42.5%#8 | — | — | — | — |
| EDIT | $405M#15 | — | 3.9x#10 | 10.0x#3 | 25.4%#4 | 32.5%#2 | -394.9%#5 | -152.0%#13 | — | — | -0.8%#9 | — |
| GRML | $492M#8 | — | 8.5x#14 | — | — | -71.6%#15 | — | -18.2%#3 | -14.6%#1 | — | -89.4%#13 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice